tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Mastocytosis, Cutaneous D034701 1 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Lung Abscess D008169 1 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Intertrigo D007402 1 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Swanson C et al. FK 506-based immunosuppression in clinical pancreas transplantation. 1995 Transplant. Proc. pmid:8539827
Tesi RJ et al. Conversion of pancreas transplants to FK 506 from CsA. 1995 Transplant. Proc. pmid:8539828
Burke GW et al. Use of FK 506 in simultaneous pancreas/kidney transplantation: lack of impairment of glycemic or lipid metabolism. 1995 Transplant. Proc. pmid:8539872
Burke GW et al. The use of FK506 in simultaneous pancreas/kidney transplantation: rescue, induction, and maintenance immunosuppression. 1995 Transplant. Proc. pmid:8539874
Klintmalm GB and Gonwa TA Nephrotoxicity associated with cyclosporine and FK506. 1995 Liver Transpl Surg pmid:9346596
Wong PY et al. FK506 in liver transplantation for chronic hepatitis B: in vitro studies on lymphocyte activation and virus replication. 1995 Liver Transpl Surg pmid:9346613
Monfar M et al. Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP. 1995 Mol. Cell. Biol. pmid:7528328
Fukuzaki T et al. A protocol with FK 506 for inducing unresponsiveness to murine islet allografts. 1995 Surgery pmid:7531371
Lemster BH et al. IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. 1995 Clin. Exp. Immunol. pmid:7531627
Schwartz M et al. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. 1995 Transplant. Proc. pmid:7533355
Yasuhara M et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. 1995 Transplant. Proc. pmid:7533356
Platz KP et al. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection. 1995 Transplant. Proc. pmid:7533357
Bierer BE Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin. 1995 Proc. Assoc. Am. Physicians pmid:8630742
Porayko MK et al. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicenter Liver Study Group. 1995 Transplant. Proc. pmid:7533358
Mueller AR et al. The superior immunosuppressant according to diagnosis: FK 506 or cyclosporine A. 1995 Transplant. Proc. pmid:7533359
Grochowicz PM et al. Synergism of castanospermine and FK 506. 1995 Transplant. Proc. pmid:7533408
Itoh S and Navia MA Structure comparison of native and mutant human recombinant FKBP12 complexes with the immunosuppressant drug FK506 (tacrolimus). 1995 Protein Sci. pmid:8563622
Tamura K et al. Inhibition of insulin production by FK 506 is caused at the transcriptional level in pancreatic beta cell when FK BP-12 content is relatively high. 1995 Transplant. Proc. pmid:7533409
Kawano K et al. Protective effect of FK 506 on hepatic injury following cold ischemic preservation and transplantation: influence on hepatic microcirculation. 1995 Transplant. Proc. pmid:7533410
Charters AR et al. Developmental expression of FK506 binding proteins and calcineurin in rat brain. 1995 Biochem. Soc. Trans. pmid:8566310
Tanabe M et al. Therapeutic synergism between low-dose FK 506 and antimetabolites in rat allogeneic heart transplantation. 1995 Transplant. Proc. pmid:7533411
Abu-Elmagd K et al. The current status of hepatic transplantation at the University of Pittsburgh. 1995 Clin Transpl pmid:8794262
Masri MA Comparative study of toxicity and efficacy of cyclosporine, cyclosporine G (OG37), FK 506, and rapamycin in BALB/c mice with fitted skin grafts. 1995 Transplant. Proc. pmid:7533412
Shapiro R et al. The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience. 1995 Clin Transpl pmid:8794266
Komori T [The change of lymphocyte subset and effect of FK506 in experimental small bowel transplantation of rats]. 1995 Nihon Geka Gakkai Zasshi pmid:7534867
Woo J et al. Combined effects of FK506 (tacrolimus) and cyclophosphamide on atypical B220+ T cells, cytokine gene expression and disease activity in MRL/MpJ-lpr/lpr mice. 1995 Clin. Exp. Immunol. pmid:7535208
Jusko WJ et al. Pharmacokinetics of tacrolimus in liver transplant patients. 1995 Clin. Pharmacol. Ther. pmid:7535213
Winkler M and Christians U A risk-benefit assessment of tacrolimus in transplantation. 1995 Drug Saf pmid:7545405
Ockenfels HM et al. Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes. 1995 Arch. Dermatol. Res. pmid:7541191
Victor RG et al. Presynaptic modulation of cortical synaptic activity by calcineurin. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7541535
Kaufman DB et al. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. 1995 Transplantation pmid:7541579
Hemenway C FK506 in bone marrow transplantation. 1995 Blood pmid:7579473
McDiarmid SV et al. The treatment of intractable rejection with tacrolimus (FK506) in pediatric liver transplant recipients. 1995 J. Pediatr. Gastroenterol. Nutr. pmid:7541834
Yamamoto M et al. Cyclosporin A and FK506 reverse anthracycline resistance by altering the cell cycle. 1995 Anticancer Drugs pmid:7579561
O'Gorman MA et al. Proximal renal tubular acidosis secondary to FK506 in pediatric liver transplant patients. 1995 Clin Transplant pmid:7579739
Saito T et al. In situ dephosphorylation of tau by protein phosphatase 2A and 2B in fetal rat primary cultured neurons. 1995 FEBS Lett. pmid:7498550
Kanamaru A et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. 1995 Bone Marrow Transplant. pmid:7581086
Antoni FA et al. Calcineurin feedback inhibition of agonist-evoked cAMP formation. 1995 J. Biol. Chem. pmid:7499291
Koehler MT et al. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation. 1995 Bone Marrow Transplant. pmid:7581088
Arnold JC and Theilmann L [Comparison between tacrolimus (FK 506) and cyclosporin in immunosuppressive therapy after liver transplantation]. 1995 Z Gastroenterol pmid:7502559
Reisman L et al. Modulation of interleukin-1 secretion by immunosuppressive drugs, alone and in combination. 1995 Transpl. Immunol. pmid:7551978
Osman A et al. Schistosoma mansoni: characterization of p50, an immunophilin. 1995 Exp. Parasitol. pmid:7537219
Tanida I et al. Cooperation of calcineurin and vacuolar H(+)-ATPase in intracellular Ca2+ homeostasis of yeast cells. 1995 J. Biol. Chem. pmid:7537264
Koch K et al. The C-32 triacetyl-L-rhamnose derivative of ascomycin: a potent, orally active macrolactone immunosuppressant. 1995 J. Med. Chem. pmid:7537331
Torii N et al. An inhibitor for calcineurin, FK506, blocks induction of long-term depression in rat visual cortex. 1995 Neurosci. Lett. pmid:7537357
Pockley AG et al. Effect of cyclosporin A, FK506 and rapamycin on proliferation and soluble IL-2 receptor release from mitogenically stimulated rat spleen cells. 1995 Biochem. Soc. Trans. pmid:8654800
Textor SC et al. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. 1995 Kidney Int. pmid:7543625
Dollinger MM et al. Tacrolimus and cardiotoxicity in adult liver transplant recipients. 1995 Lancet pmid:7543645
Romero DF et al. Rapamycin: a bone sparing immunosuppressant? 1995 J. Bone Miner. Res. pmid:7543725
Rebollo A et al. Differential effect of rapamycin and cyclosporin A in proliferation in a murine T cell line expressing either intermediate or high affinity receptor for IL-2. 1995 Cytokine pmid:7543780
Lam E et al. Isolation of a cDNA encoding a novel human FK506-binding protein homolog containing leucine zipper and tetratricopeptide repeat motifs. 1995 Gene pmid:7543869
Hisatomi K et al. Changes in the mononuclear cell subpopulations of rat cardiac transplant recipients administered FK506 for the treatment of ongoing rejection. 1995 Surg. Today pmid:7539647
Tamura K et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. 1995 Transplantation pmid:7539960
Fisher A et al. FK506 hepatotoxicity in liver allograft recipients. 1995 Transplantation pmid:7539961
Teague S Lessons from molecular matchmakers. 1995 Nat. Struct. Biol. pmid:7545076
Ito T et al. Immunosuppressive agents induce the reduction of local pancreatic blood flow. 1995 Pancreas pmid:7545292
Han CW et al. Differential effects of the immunosuppressants cyclosporin A, FK506 and KM2210 on cytokine gene expression. 1995 Bone Marrow Transplant. pmid:7545487
Hattori Y and Nakanishi N Effects of cyclosporin A and FK506 on nitric oxide and tetrahydrobiopterin synthesis in bacterial lipopolysaccharide-treated J774 macrophages. 1995 Cell. Immunol. pmid:7545550
Yeh WC et al. Identification and characterization of an immunophilin expressed during the clonal expansion phase of adipocyte differentiation. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7479941
Han JW et al. Rapamycin, wortmannin, and the methylxanthine SQ20006 inactivate p70s6k by inducing dephosphorylation of the same subset of sites. 1995 J. Biol. Chem. pmid:7545671
Yeh WC et al. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7479942
Shaw KT et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7479966
Annesley TM et al. Stability of tacrolimus (FK 506) and cyclosporin G in whole blood. 1995 Ther Drug Monit pmid:7482690
Lake JR et al. The impact of immunosuppressive regimens on the cost of liver transplantation--results from the U.S. FK506 multicenter trial. 1995 Transplantation pmid:7482713
Stratta RJ et al. Preliminary experience with FK 506 in pancreas transplant recipients. 1995 Transplant. Proc. pmid:8539823
Díaz M et al. [Tacrolimus (FK 506): an immunosuppression alternative in solid organ transplantation. (Part 2)]. 1995 Apr-Jun Rev Med Univ Navarra pmid:7569553
Hisatomi K et al. Effect of dose of cyclosporine or FK506 and antithrombotic agents on cardiac allograft vascular disease in heterotopically transplanted hearts in rats. 1995 Jan-Feb J. Heart Lung Transplant. pmid:7537098
Díaz M et al. [Tacrolimus (FK 506): immunosuppressive alternative to solid organ transplant (Part 1)]. 1995 Jan-Mar Rev Med Univ Navarra pmid:14735715
Kawahara K et al. Effects of deoxyspergualin on bronchial anastomosis healing in canine pulmonary allografts. 1995 Jul-Aug J. Heart Lung Transplant. pmid:7578196
Motoyama K et al. Pretransplant intrathymic inoculation of donor antigen combined with FK506 treatment: prolongation of survival of cardiac, but not renal, allografts in rats. 1995 Mar-Apr World J Surg pmid:7538717
Okudaira H et al. Enhanced production and gene expression of interleukin-5 in patients with bronchial asthma: possible management of atopic diseases by down-regulation of interleukin-5 gene transcription. 1995 May-Jun Int. Arch. Allergy Immunol. pmid:7542077
Su Q et al. Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase. 1995 May-Jun Ren. Physiol. Biochem. pmid:7542793
Hayashi S et al. Evidence that donor pretreatment with FK506 has a synergistic effect on graft prolongation in hamster-to-rat heart xenotransplantation. 1995 May-Jun J. Heart Lung Transplant. pmid:7544621
Castillo Lugo JA Clinical and experimental immunosuppression. 1995 May-Jun Bol Asoc Med P R pmid:8573248
Seifeldin R Drug interactions in transplantation. 1995 Nov-Dec Clin Ther pmid:8750397
Schreiber SL and Crabtree GR Immunophilins, ligands, and the control of signal transduction. 1995-1996 Harvey Lect. pmid:9127988
Panyi G et al. Immunosuppressors inhibit voltage-gated potassium channels in human peripheral blood lymphocytes. 1996 Biochem. Biophys. Res. Commun. pmid:8619842
Kiang D et al. Cloning the gene encoding Schistosoma mansoni p50, an immunophilin. 1996 Gene pmid:8621074
Sung RS et al. Survival of human islet xenografts irradiated with ultraviolet B in diabetic rats. 1996 Transplant. Proc. pmid:8623427
Pirenne J et al. Addition of the colon to small bowel grafts causes lethal graft-versus-host disease in FK 506-treated pigs. 1996 Transplant. Proc. pmid:8623447
Mori A et al. Enhanced production and gene expression of IL-5 in bronchial asthma. Possible management of atopic diseases with IL-5 specific gene transcription inhibitor. 1996 Adv. Exp. Med. Biol. pmid:9095279
Morozumi K et al. Diagnosis of chronic rejection using peritubular and glomerular capillary lesions. 1996 Transplant. Proc. pmid:8644331
Buckle GJ et al. HTLV-I-induced T-cell activation. 1996 J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. pmid:8797712
Platz KP et al. Management of acute steroid-resistant rejection after liver transplantation. 1996 World J Surg pmid:8798364
Bardella MT et al. FK 506 and cyclosporine: effect on D-xylose absorption in pigs with orthotopic liver-small bowel allotransplants. 1996 Transplant. Proc. pmid:8907937
Sugitani A et al. Intestinal neurons in acute and chronic rejection after small bowel transplantation in dogs. 1996 Transplant. Proc. pmid:8907941
Ankarcrona M et al. Calcineurin and mitochondrial function in glutamate-induced neuronal cell death. 1996 FEBS Lett. pmid:8830666
Alessiani M et al. Combined immunosuppressive therapy with tacrolimus and mycophenolate mofetil for small bowel transplantation in pigs. 1996 Transplantation pmid:8830816
Rambusch EG and Manns MP [Therapy of autoimmune hepatitis]. 1996 Dtsch. Med. Wochenschr. pmid:8998922
Yokoyama I et al. Decreased Fas antigen expression of cultured hepatocytes with FK 506. 1996 Transplant. Proc. pmid:8962237
Mueller AR et al. Long-term follow-up in hepatitis C patients with respect to immunosuppression. 1996 Transplant. Proc. pmid:8962255
Hisatomi A et al. Effect of Prograf (FK506) on spermatogenesis in rats. 1996 Toxicology pmid:8658548
Harihara Y et al. Effects of interferon alpha/beta on cardiac allografts. 1996 Transplant. Proc. pmid:8658645
Budde K et al. Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. 1996 Int J Clin Pharmacol Ther pmid:8937932
Ide T et al. An immunosuppressant, FK506, protects hippocampal neurons from forebrain ischemia in the mongolian gerbil. 1996 Neurosci. Lett. pmid:8938254
Alak AM and Lizak PP Quality assurance procedure for monitoring tacrolimus (FK506) concentrations in whole blood by IMx assay. 1996 Ther Drug Monit pmid:8738766
Ockenfels HM et al. Inhibition of T cell cAMP formation by cyclosporin A and FK506. 1996 Naunyn Schmiedebergs Arch. Pharmacol. pmid:8740144
Ohshima S et al. Immunosuppressive treatment of primary cadaveric renal transplant patients receiving kidneys from non-heart beating donors. 1996 Artif Organs pmid:8896734
Yagita Y et al. Effect of immunosuppressant FK506 on ischemia-induced degeneration of hippocampal neurons in gerbils. 1996 Life Sci. pmid:8913329
Dhar DK et al. FK506 maintains cellular calcium homeostasis in ischemia-reperfusion injury of the canine liver. 1996 J. Surg. Res. pmid:8592405